FDA grants orphan-drug designation for TauRx’s LMTX in frontotemporal dementia
FDA grants orphan-drug designation for TauRx’s LMTX in frontotemporal dementia
ABERDEEN, Scotland and Singapore, 10th December, 2018 – TauRx, a leader in neurodegenerative disease research, today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to LMTX® for the
"treatment of frontotemporal dementia". The term Frontotemporal Dementia (FTD) covers a number of sub-types of dementia, all of which are characterized by a progressive loss of neurons in the frontal and/or temporal lobes of the brain.
Read more here.
FDA grants orphan-drug designation for LMTX
TauRx, a leader in neurodegenerative disease research, today announced that the US Food and Drug Administration (FDA) has granted orphan-drug designation for
Recent News
LUCIDITY phase 3 topline data presented at CTAD for HMTM - the only oral anti-Tau therapy in late-stage development
Dec 02, 2022
TauRx Announces Additional Investment of USD119 million following announcement of Phase 3 LUCIDITY Topline Results
Nov 14, 2022
TauRx Pharmaceuticals Ltd has announced further results from its Phase 3 LUCIDITY trial for Hydromethylthionine mesylate (HMTM)
Oct 06, 2022
TauRx Pharmaceuticals Ltd is delighted to name Dr Richard Stefanacci, an established global key opinion leader in Alzheimer’s, as Chief Medical Officer (CMO)
Oct 06, 2022